HLA Alleles Associate with Insulin Autoimmune Syndrome

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2024-09-16 DOI:10.2147/dmso.s456466

Dan Yao, Jiefeng Jiang, Qianyun Zhou, Caiyun Feng, Jianping Chu, Zhiyan Chen, Jie Yang, Jinying Xia, Yujia Chen

{"title":"HLA Alleles Associate with Insulin Autoimmune Syndrome","authors":"Dan Yao, Jiefeng Jiang, Qianyun Zhou, Caiyun Feng, Jianping Chu, Zhiyan Chen, Jie Yang, Jinying Xia, Yujia Chen","doi":"10.2147/dmso.s456466","DOIUrl":null,"url":null,"abstract":"Abstract: In recent years, there have been hundreds of reports on insulin autoimmune syndrome (IAS) globally; however, fewer than a hundred patients have undergone genetic testing. Our objective is to examine the background of IAS and the variations in drugs that trigger it among patients who have been genetically tested, aiming to deepen our understanding of this condition. HLA Analysis of 68 cases showed that DR4 is predominant, especially in individuals of East Asian descent, notably in DRB1 &ast0406. Methimazole was the primary drug associated with IAS in these populations, while in Caucasian individuals, the emphasis was on DRB1 &ast0403, with lipoic acid being the common inducer. The key factor determining disease risk is the combination of chromosomal allele variations, with HLA class II allele DR4 positive patients showing a strong association with DQA1 &ast0301/DQB1 &ast0302. Keywords: insulin autoimmune syndrome, HLA, methimazole, α-lipoic acid ","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/dmso.s456466","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: In recent years, there have been hundreds of reports on insulin autoimmune syndrome (IAS) globally; however, fewer than a hundred patients have undergone genetic testing. Our objective is to examine the background of IAS and the variations in drugs that trigger it among patients who have been genetically tested, aiming to deepen our understanding of this condition. HLA Analysis of 68 cases showed that DR4 is predominant, especially in individuals of East Asian descent, notably in DRB1 &ast0406. Methimazole was the primary drug associated with IAS in these populations, while in Caucasian individuals, the emphasis was on DRB1 &ast0403, with lipoic acid being the common inducer. The key factor determining disease risk is the combination of chromosomal allele variations, with HLA class II allele DR4 positive patients showing a strong association with DQA1 &ast0301/DQB1 &ast0302.

Keywords: insulin autoimmune syndrome, HLA, methimazole, α-lipoic acid

查看原文本刊更多论文

与胰岛素自身免疫综合征有关的 HLA 等位基因

摘要：近年来，全球关于胰岛素自身免疫综合征（IAS）的报道数以百计，但接受过基因检测的患者不足百人。我们的目的是研究胰岛素自身免疫综合征的背景，以及接受基因检测的患者中引发该病的药物变异，从而加深我们对该病的了解。对68例病例的HLA分析表明，DR4占主导地位，尤其是在东亚后裔中，特别是在DRB1 &ast0406中。在这些人群中，甲巯咪唑是与 IAS 相关的主要药物，而在白种人中，重点是 DRB1 &ast0403，硫辛酸是常见的诱导剂。决定疾病风险的关键因素是染色体等位基因变异的组合，HLA II类等位基因DR4阳性患者与DQA1 &ast0301/DQB1 &ast0302 有很强的关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.